Pall Corp. (NYSE: PLL) 8.7% HIGHER; reports Q3 EPS of $0.40, ex-items, inline with the analyst estimate of $0.40.
Revenue for the quarter was $546.9 million, which compares to the estimate of $558.98 million. Cytokinetics, Incorporated (NASDAQ: CYTK) 6.7% LOWER; Cytokinetics announced that it has agreed with GlaxoSmithKline (NYSE: GSK) to terminate their collaboration and license agreement, effective February 28, 2010.
As a result, all rights for GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), will revert to Cytokinetics effective...
Post new comment